Three leading cancer organizations have released new recommendations on the use of post-mastectomy radiation therapy (PMRT) in breast cancer treatment, offering updated guidance to help physicians tailor care to individual patients.
The American Society for Radiation Oncology (ASTRO), the American Society of Clinical Oncology (ASCO), and the Society of Surgical Oncology (SSO) jointly published the guideline in their journals, including Practical Radiation Oncology, the Journal of Clinical Oncology, and Annals of Surgical Oncology.
Why PMRT Matters
Each year, more than 100,000 Americans undergo mastectomy as part of breast cancer treatment. For many, radiation therapy after surgery reduces the risk of the cancer coming back. PMRT works by targeting areas where microscopic cancer cells may remain, lowering recurrence risk and supporting long-term survival.
“Radiation therapy after a mastectomy can substantially reduce the risk of cancer returning and extend survival for many patients with invasive breast cancer,” said Dr. Rachel B. Jimenez, co-chair of the expert panel and radiation oncologist at Massachusetts General Hospital.
What’s New in the Guidelines
The updated recommendations reflect advances in cancer diagnostics and treatment approaches, including:
More personalized care: Tools now help doctors identify which patients benefit most from radiation.
Improved techniques: Advances like intensity-modulated radiation therapy (IMRT) and deep inspiration breath hold reduce side effects while maintaining precision.
Smaller treatment areas: In some cases, PMRT can be limited to the chest wall instead of broader nodal regions, lowering treatment burden.
Focus on teamwork: Decisions should be made through shared discussions between patients and multidisciplinary care teams.
“These recommendations help bring clarity to a complex decision, providing a roadmap for when and how PMRT should be used,” said Dr. Kathleen C. Horst, panel co-chair and radiation oncologist at Stanford University.
Key Takeaways from the Guidelines
Patients with node-positive disease: PMRT is generally recommended, though some low-risk patients may safely avoid it.
Patients with node-negative disease: PMRT may be advised for those with larger tumors or higher-risk features but is usually unnecessary for small tumors without nodal involvement.
Patients treated before surgery (neoadjuvant therapy): PMRT is recommended if cancer remains in lymph nodes or if the disease was locally advanced at diagnosis.
Treatment delivery: Moderate hypofractionation (shorter, higher-dose treatments) is preferred, and advanced imaging techniques are recommended to improve precision.
Moving Toward More Individualized Care
While PMRT remains an essential tool for many patients, the updated guideline emphasizes tailoring treatment to each person’s unique cancer profile and preferences.
“This guideline incorporates the most recent and relevant data to help us individualize care while acknowledging where knowledge gaps remain,” said Dr. Cindy Matsen, surgical oncologist and SSO representative on the panel.
The new guideline is endorsed by the American Society of Breast Surgeons and the Royal Australian and New Zealand College of Radiologists. It updates previous recommendations last revised in 2016.
YOU MAY ALSO LIKE
